Letting post-marketing bridge the evidence gap: the case of orphan drugs.

Roberta Joppi, Chiara Gerardi, Vittorio Bertele', Silvio Garattini

Journal: BMJ (Clinical research ed.) 2017;353():i2978

PMID: 27335134

Abstract

Address: IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy Pharmaceutical Department, Local Health Unit of Verona, Via Salvo D'Acquisto 7, 37122 Verona, Italy [email protected].; IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.

DOI: 10.1136/bmj.i2978

Link outs

Free resources

Other Literature Sources:

https://scite.ai/reports/27335134

Miscellaneous:

https://assays.cancer.gov/CPTAC-1548

Subscription / membership required

Full Text Sources:

MeSH Terms: Adrenal Cortex Neoplasms, Adrenocortical Carcinoma, Anti-Inflammatory Agents, Non-Steroidal, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Barrett Esophagus, Cladribine, Dihematoporphyrin Ether, Ductus Arteriosus, Patent, Hepatolenticular Degeneration, Humans, Ibuprofen, Leukemia, Hairy Cell, Mitotane, Orphan Drug Production, Platelet Aggregation Inhibitors, Product Surveillance, Postmarketing, Quinazolines, Thrombocythemia, Essential, Zinc Acetate

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.